Mounjaro Tirzepatide 15 mg Injection: What the Trial Data Actually Shows

What SURMOUNT-1 actually measured at the 15 mg dose

The SURMOUNT-1 trial was a 72-week randomised, placebo-controlled study involving 2,539 adults with a BMI of 30 or above (or 27 and above with at least one weight-related condition) who did not have type 2 diabetes. Participants on tirzepatide 15 mg lost an average of around 20–21% of their body weight by week 72, with some analyses reporting up to approximately 22.5% in those who completed the full course. That is a meaningful distinction from earlier generations of weight-management medicines, and it is part of why NICE recommended tirzepatide in its appraisal TA1026, published in December 2024.

The mechanism behind those numbers matters. Tirzepatide activates two gut-hormone receptors simultaneously (GIP and GLP-1) which together slow gastric emptying, reduce appetite and influence blood-sugar regulation. No other weight-loss medicine licensed in the UK works across both pathways. The 15 mg dose represents the full expression of that dual action after the body has had time to adjust through the earlier steps in the schedule.

It is worth being honest about what trial data can and cannot tell you. The 20–21% figure is an average across thousands of participants; individual responses varied. Some people lost considerably more, others less. A prescriber reviewing your health history is better placed to set expectations than any headline statistic.

Why the titration path to 15 mg is the point, not a delay

Reaching 15 mg takes time by design. The licensed UK schedule starts at 2.5 mg, a dose whose job is to let your digestive system settle before any meaningful weight-related effect begins. Dose steps typically happen in four-weekly increments, guided by tolerability, and a prescriber decides whether to increase, hold or adjust at each stage. The full titration ladder runs 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and finally 15 mg.

If you are already a few steps into treatment and wondering what comes next, the overview of tirzepatide injection doses explains how each step in the schedule is structured. For those at the very start of the journey, the process and what to expect at the 2.5 mg starting dose is worth reading first.

The clinical reasoning for this approach is straightforward. Gastrointestinal side effects (nausea, vomiting, loose stools) are most likely to appear when the dose increases. A slow step-up gives the body time to adapt and reduces the chance of stopping treatment early because of discomfort that would, in most cases, have settled within days to a couple of weeks. Rushing to the top dose is not supported by the evidence and is not how the medicine is prescribed.

Many people find the titration process less daunting once they realise each step is doing something specific, not just marking time. That reassurance comes up often in clinical practice.

Who reaches 15 mg, and what the eligibility picture looks like

Not everyone on Mounjaro reaches 15 mg, and that is not a failure. The prescriber's role at each review is to find the highest tolerated dose, which differs between individuals. Some achieve substantial weight loss at 10 mg and do not need to go further. Others tolerate 15 mg comfortably from the first step up to it.

The licensed eligibility criteria for tirzepatide in the UK require a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. The NHS tirzepatide medicines page covers these criteria clearly, alongside a plain-English summary of how the medicine works.

NICE TA1026 sets additional NHS eligibility thresholds, a BMI of 35 and above with at least one weight-related comorbidity is required for NHS access, though those criteria are being phased in across different cohorts through 2025 and into 2027. Private prescribing through a regulated pharmacy follows the licensed SmPC criteria, with a prescriber assessing the full clinical picture regardless of route. If you are weighing up NHS versus private access, the Mounjaro treatment overview lays out both paths clearly.

Side effects at the top dose and when to seek medical attention

The side-effect profile at 15 mg is broadly the same as at lower doses, nausea, indigestion, constipation, diarrhoea, burping and fatigue are the most commonly reported. They tend to be most noticeable in the days following a dose increase and often ease within a week or two as the body adjusts. If you have recently moved up to the 5 mg pen and want to understand how your body may respond at that particular step, our guide to the Mounjaro injection 5mg covers what to expect in practical terms. Injection-site reactions can occur; rotating between the abdomen, thigh and upper arm for each weekly injection reduces this.

A small number of more serious reactions require prompt attention. The MHRA highlighted acute pancreatitis in a Drug Safety Update in January 2026: severe, persistent stomach pain (particularly if it spreads towards the back, with or without vomiting) warrants urgent medical assessment. Symptoms suggesting gallbladder problems, signs of a serious allergic reaction, or significant dehydration from prolonged vomiting or diarrhoea should also be treated as reasons to contact a doctor or call 111 without delay.

Any suspected side effects, including those that appear minor, can be reported through the Yellow Card scheme. The MHRA uses those reports to build the ongoing safety picture for medicines that, like Mounjaro, carry Black Triangle status because they are still in the post-approval monitoring phase.

For anyone considering treatment or currently mid-titration and wondering whether 15 mg is on the horizon for them, speaking directly with a prescriber is the most useful step. If you are already using the 5 mg strength and want a closer look at the formulation itself, our page on the Mounjaro tirzepatide injection 5mg has the detail you need. Those who want to understand the broader dosing framework before their next review will find that our resource on tirzepatide injection dosage sets out how prescribers approach each stage of treatment. Our free consultation connects you with a GPhC-registered prescriber who can review your history and answer questions specific to your situation. There are also general FAQs covering the most common questions our clinical team receives, and you can find out more about the clinical oversight behind the service on the clinical team page.